Latest Options News

DataWorks has secured a significant contract extension with iGaming Ontario, adding over C$12.5 million to its Centralised Self-Exclusion program services. This move strengthens its recurring revenue and solidifies its RegTech division’s profitability.

Barton Gold Holdings has launched a Definitive Feasibility Study and appointed Bedrock Advisory Partners to steer financing for its Stage 1 operations at Central Gawler Mill, following a significant resource upgrade.

First Graphene has secured a strategic distribution and collaboration agreement with Syron GreenThrust Dynamics to supply its PureGRAPH products across India, SAARC nations, and the UAE, unlocking new industrial markets and potential local manufacturing.

AuKing Mining Ltd has kicked off a $2 million share placement with a first tranche completed and seeks shareholder approval for the second. The company also plans a fresh marketing partnership with Singapore’s Bullseye Analytics, issuing options as part of the deal.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for four Australian iShares ETFs, outlining key dates and options for investors to reinvest dividends.

Strickland Metals has announced a significant new gold and base metals discovery at its Rogozna Project in Serbia, expanding the potential of its already substantial mineral resources. The discovery at Red Creek lies just 1km from the major Shanac Deposit, promising further growth opportunities.

Pinnacle Investment Management Group Limited has announced a fully franked ordinary dividend of AUD 0.29 per share for the half-year ending December 2025, with a dividend reinvestment plan available to shareholders.

The Federal Court of Australia has approved the acquisition schemes for Global Uranium and Enrichment Limited by Snow Lake Resources, setting the stage for a significant shift in shareholder structure and market listing.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.